Targeting the Src pathway enhances the efficacy of selective FGFR inhibitors in cancers with FGFR3 alterations
N. C. Lima, E. Atkinson, T. D. Bunney, M. Katan, P. H. Huang
This study shows that combining Src pathway inhibitors with FGFR inhibitors improves efficacy in cancers with FGFR3 mutations by overcoming intrinsic resistance.
bioRxiv · Apr 4, 2020Cancer Biology